HIV Drug Market Share, Trends & Forecast - 2022

1
HIV Drug Market
Opportunities and Forecasts, 2014 - 2022
Pages 163 Published 2017
2
 
HIV DRUG MARKET MARKET
 North America and Europe are expected to
dominate the global HIV drug market during the
forecast period, while emerging countries in
Asia-Pacific and Latin America are expected to
offer significant growth opportunities. Hemali
Narkhede
3
 
HIV DRUG MARKET MARKET OVERVIEW

• HIV Drug Market report, published by Allied
  Market Research, forecasts that the global market
  is expected to garner 26,458 million by 2022,
  registering a CAGR of 3.7 during the period 2016
  - 2022. 
• The multi-class combination drug segment held
  over one-third share of the total market in 2015.
• Multi-class combination drugs segment had
  accounted for more than one-third revenue of the
  overall HIV drug market in 2015, owing to
  increase in adoption of combination drugs from
  this medication class due to their better results
  in the control of HIV related coinfections and
  their ease in consumption adherence. 
• Read more at https//www.alliedmarketresearch.co
  m/hiv-drugs-market

4
 
HIV DRUG MARKET MARKET KEY BENEFITS

• The study provides an in-depth analysis of the
  HIV drugs market, with current trends and future
  estimations to elucidate the imminent investment
  pockets.
• It presents a quantitative analysis from 2014 to
  2022 to enable the stakeholders to capitalize on
  prevailing market opportunities.
• Extensive analysis of the HIV drug market, by
  medication class, assists in the effective
  treatment of HIV/AIDS.
• Key players are profiled and their strategies are
  analyzed thoroughly, which predicts the
  competitive outlook of the market.

5
 
HIV DRUG MARKET MARKET TOP INVESTMENT POCKETS
6
 
HIV DRUG MARKET MARKET KEY FINDINGS

• In 2015, multi-class combination drugs segment
  was the leading medication class segment.
• The branded drug Triumeq of multi-class
  combination drug segment is estimated to grow at
  the CAGR of 20.7.
• North America market is projected to grow at a
  CAGR of 3.4 during analysis period.
• The Nucleoside Reverse Transcriptase Inhibitors
  (NRTIs) segment is estimated to grow at the CAGR
  of 0.4.

7
 
KEY PLAYERS IN INDUSTRY

• Boehringer Ingelheim International GmbH
• Merck Co., Inc.
• ViiV Healthcare
• AbbVie
• F. Hoffmann-La Roche Ltd.
• Teva Pharmaceutical Industries Ltd.
• Bristol-Myers Squibb
• Gilead Sciences, Inc.
• Johnson Johnson
• Cipla Limited
• Download Sample Report
• https//www.alliedmarketresearch.com/request-free-
  sample/1867

8
 
HIV DRUG MARKET SEGMENTATION
9
 
HIV DRUG MARKET MARKET BY GEOGRAPHY
North America Europe Asia-Pacific LAMEA
10
 
 
Thank You! For More Details
Visit us at
https//www.alliedmarketresearch.com/hiv-drugs-mar
ket
Follow Us On